Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Acasti Pharma, Inc. (ACST)
Last acasti pharma, inc. earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: GlobeNewswire
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that patient enrollment has been completed in the Company’s Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405). The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in 100 patients hospitalized for aSAH. Approximately 25 hospitals in the U.S. are participating. “We are excited to announce the completion of enrollment in our STRIVE-ON trial, a significant milestone for the Company achieved ahead of our original expectations,” said Prashant Kohli, CEO of Acasti. “I'm proud of our team's diligence in executing the clinical trial plan, and thankful to our investigator
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. [Canadian Business Journal (Canada)]Canadian Business Journal
- Acasti Pharma changes name to Grace Therapeutics [Seeking Alpha]Seeking Alpha
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.GlobeNewswire
- Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Acasti Pharma Inc. (NASDAQ: ACST) had its price target raised by analysts at Craig Hallum from $6.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
ACST
Earnings
- 8/9/24 - Beat
ACST
Sec Filings
- 10/28/24 - Form 8-K
- 10/25/24 - Form 8-K
- 10/16/24 - Form EFFECT
- ACST's page on the SEC website